drugset
drugset / Trial / NCT04337463

ATG-008 Combined With Toripalimab in Advanced Solid Tumors

NCT04337463 ↗

Phase 1/2 Unknown 60 enrolled Sichuan University
NaSequentialOpen-labelTreatment

Summary

This is an open-label, single-arm study with dose-escalation and expansion phases to access ATG-008 combined with Toripalimab in patients with advanced solid tumors.

Timeline

Start
2020-04-23
Primary completion
2022-05-01
Completion
2022-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ONATASERTIB Small molecule — —
Subject Toripalimab Monoclonal antibody — Intravenous

Indications

neoplasm